E. Clark

发表

Photodynamic versus white light-guided treatment of non-muscle invasive bladder cancer: a study protocol for a randomised trial of clinical and cost-effectiveness

C. Ramsay, J. Norrie, Jing Shen, 2019, BMJ Open.

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Sung-Bae Kim, J. Baselga, S. Swain, 2012, The New England journal of medicine.

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.

Sung-Bae Kim, A. Schneeweiss, J. Baselga, 2015, The New England journal of medicine.

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up

R. Gelber, M. Piccart, G. Viale, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prostate cancer androgen receptor splice variant 7 biomarker study - a multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (the VARIANT trial) study protocol

D. Howel, J. Staffurth, I. Pedley, 2019, BMJ Open.

Abstract GS1-04: Interim overall survival analysis of APHINITY (BIG 4-11): A randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-pos

R. Gelber, M. Piccart, G. Viale, 2020 .

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.

Sung-Bae Kim, A. Schneeweiss, S. Loi, 2020, The Lancet. Oncology.

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

K. C. Morris, Mohammed Salah Ibrahim, K. Y. Wong, 2022, medRxiv.

Glofitamab Monotherapy Provides Durable Responses after Fixed-Length Dosing in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (pts)

A. Salar, E. W. Van Den Neste, N. Bartlett, 2021, Blood.

Timelines to initiate a phase III trial across the globe: a sub-analysis of the APHINITY trial

M. Procter, E. de Azambuja, N. Pondé, 2022, Ecancermedicalscience.

Photodynamic versus white-light-guided resection of first-diagnosis non-muscle-invasive bladder cancer: PHOTO RCT.

C. Ramsay, A. Feber, J. Norrie, 2022, Health technology assessment.

Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer

R. Gelber, M. Piccart, J. Baselga, 2021, British Journal of Cancer.

Exposure–response analysis of pertuzumab in HER2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parameters

J. Marier, E. Clark, J. Cortés, 2013, Cancer Chemotherapy and Pharmacology.

Quality of life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer.

J. Baselga, S. Swain, Y. Im, 2012 .

Stage‐for‐stage comparison of definitive chemoradiotherapy, surgery alone and neoadjuvant chemotherapy for oesophageal carcinoma (Br J Surg 2009; 96: 1300–1307)

E. Clark, S. Griffin, A. Robertson, 2010, The British journal of surgery.

Using the AR-V7 biomarker to determine treatment in metastatic castrate resistant prostate cancer, a feasibility randomised control trial, conclusions from the VARIANT trial

I. Pedley, S. Crabb, E. Clark, 2022, NIHR open research.

Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.

S. Fox, S. Loi, J. Baselga, 2017, The Lancet. Oncology.

Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.

J. Baselga, S. Swain, S. Im, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)

D. Amadori, J. Baselga, P. Sunpaweravong, 2013, Breast Cancer Research and Treatment.

Adjuvant Pertuzumab and Trastuzumab in Early HER2‐Positive Breast Cancer

Marion Procter, Thomas Suter, R. Gelber, 2017, The New England journal of medicine.

A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer.

M. Dowsett, J. Mayordomo, J. Salter, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma.

R. Greil, G. Salles, A. Zelenetz, 2020, Blood.

Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA.

J. Baselga, S. Swain, D. Miles, 2014, The oncologist.

Results From the Phase III Trial CLEOPATRA Asia With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Safety Profile of Pertuzumab With Trastuzumab and Docetaxel in Patients From

J. Baselga, S. Swain, D. Miles, 2014 .

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

Sung-Bae Kim, A. Schneeweiss, J. Baselga, 2013, The Lancet. Oncology.

End-of-study analysis from the phase III, randomized, double-blind, placebo (Pla)-controlled CLEOPATRA study of first-line (1L) pertuzumab (P), trastuzumab (H), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC).

Sung-Bae Kim, A. Schneeweiss, S. Swain, 2019, Journal of Clinical Oncology.

Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study.

D. Amadori, J. Baselga, S. Swain, 2013, The oncologist.

Glofitamab Step-up Dosing Induces High Response Rates in Patients (pts) with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Most of Whom Had Failed Prior Bruton's Tyrosine Kinase Inhibitor (BTKi) Therapy

J. Zaucha, N. Bartlett, T. Phillips, 2021, Blood.

A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma.

R. Greil, G. Salles, A. Zelenetz, 2021, Blood.

Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

C. Carlo-Stella, M. Hutchings, E. Clark, 2022, The New England journal of medicine.

Reply to a. Avan et Al.

J. Baselga, S. Swain, E. Clark, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

350O_PRFINAL OVERALL SURVIVAL (OS) ANALYSIS FROM THE CLEOPATRA STUDY OF FIRST-LINE (1L) PERTUZUMAB (PTZ), TRASTUZUMAB (T), AND DOCETAXEL (D) IN PATIENTS (PTS) WITH HER2-POSITIVE METASTATIC BREAST CANCER (MBC)

A. Schneeweiss, J. Baselga, S. Swain, 2014 .

Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in the CLEOPATRA study.

J. Baselga, S. Swain, E. Clark, 2012 .

VP6-2022: Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years' follow-up

M. Piccart, J. Jassem, S. Loibl, 2022, Annals of Oncology.

Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial.

R. Gelber, S. Loi, F. Cardoso, 2022, European journal of cancer.

The effects of physical activity, fast-mimicking diet and psychological interventions on cancer survival: A systematic review and meta-analysis of randomized controlled trials

E. Clark, P. Cannon, Hannah Maguire, 2020, Complementary therapies in medicine.

Adverse events with pertuzumab and trastuzumab: Evolution during treatment with and without docetaxel in CLEOPATRA.

J. Baselga, S. Swain, X. Pivot, 2012 .

Abstract S5-1: Biomarker analyses in CLEOPATRA: A phase III, placebo-controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC)

J. Baselga, S. Swain, J. Cortes, 2012 .

Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and ≥ 2 prior therapies: Pivotal phase II expansion results.

C. Carlo-Stella, M. Hutchings, E. Clark, 2022, Journal of Clinical Oncology.

Photodynamic Diagnosis-guided Transurethral Resection of Bladder Tumour in Participants with a First Suspected Diagnosis of Intermediate- or High-risk Non–muscle-invasive Bladder Cancer: Cost-effectiveness Analysis Alongside a Randomised Controlled Trial

S. Penegar, Z. Tandoğdu, Rebecca Lewis, 2023, European urology open science.

Patient (pt)-reported function and symptoms in APHINITY: A randomized comparison of chemotherapy (C) + trastuzumab (H) + placebo (Pla) versus C + H + pertuzumab (P) as adjuvant therapy in pts with HER2-positive early breast cancer (EBC).

R. Gelber, J. Baselga, G. Viale, 2018 .

J. Baselga, S. Swain, X. Pivot, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

R. Gelber, M. Piccart, J. Baselga, 2019, Clinical breast cancer.

Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.

S. Fox, S. Loi, J. Baselga, 2017, The Lancet. Oncology.

GLOFITAMAB STEP‐UP DOSING: UPDATED EFFICACY DATA SHOW HIGH COMPLETE RESPONSE RATES IN HEAVILY PRETREATED RELAPSED/REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL) PATIENTS

E. Piccione, C. Haioun, C. Carlo-Stella, 2021, Hematological Oncology.